Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells
Top Cited Papers
Open Access
- 8 January 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 11 (5), 1100-1117
- https://doi.org/10.1158/2159-8290.cd-20-1445
Abstract
Combined blockade of CTLA4 and the PD-1–PD-L1 axis can be effective but is limited by immune-related adverse events, prompting the development of a bispecific antibody (MEDI5752) targeting PD-1 and CTLA4; this treatment limited tumor growth in vivo.Keywords
Other Versions
Funding Information
- AstraZeneca
This publication has 59 references indexed in Scilit:
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumorsJCI Insight, 2013
- Constitutive Clathrin-mediated Endocytosis of CTLA-4 Persists during T Cell ActivationJournal of Biological Chemistry, 2012
- The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responsesNature Reviews Immunology, 2011
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4Science, 2011
- Guidelines for the welfare and use of animals in cancer researchBritish Journal of Cancer, 2010
- Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood, 2009
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodiesThe Journal of Experimental Medicine, 2009
- Structural characterization of a human Fc fragment engineered for lack of effector functionsActa crystallographica. Section D, Structural biology, 2008
- CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast KineticsThe Journal of Experimental Medicine, 1997
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994